Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now ...

Expert Rev Anticancer Ther. 2009;9(9):1305-1316. Very recently, the addition of bortezomib to chemotherapy was evaluated in DLBCL patients relapsing after R-CHOP. [49] To test the hypothesis that ...

Autologous-hematopoietic Stem Cell Transplantation for Diffuse Large B-cell Non-Hodgkin Lymphoma Despite recent advances in the treatment of non-Hodgkin lymphoma (NHL), some patients with advanced ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL ... It is the most common form of non-Hodgkin lymphoma (NHL), accounting for ...

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

ARV-393 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein ...